Your browser doesn't support javascript.
loading
A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations.
Wang, Pingli; Cao, Liming; Tian, Panwen; Ren, Shengxiang; Miao, Liyun; Zhou, Chengzhi; Fan, Yun; Li, Yuping; Lv, Dongqing; Zhao, Xin; Yang, Mei; Zhu, Chaonan; Yu, Bing; Xu, June; Song, Yong; Wang, Kai.
Afiliación
  • Wang P; Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
  • Cao L; Department of Respiratory Medicine, Xiangya Hospital Central South University, Changsha, Hunan, P. R. China.
  • Tian P; Department of Respiratory and Critical Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, P. R. China.
  • Ren S; Department of Medical Oncology, Shanghai Pulmonary Hospital, Shanghai, P. R. China.
  • Miao L; Department of Respiratory Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, Jiangsu, P. R. China.
  • Zhou C; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, P. R. China.
  • Fan Y; Department of Medical Thoracic Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Hangzhou, Zhejiang, P. R. China.
  • Li Y; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P. R. China.
  • Lv D; Department of Respiratory Medicine, Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, P. R. China.
  • Zhao X; Department of Respiratory and Critical Care Medicine, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, P. R. China.
  • Yang M; Huadong Global Development Center, Hangzhou ZhongMei HuaDong Pharmaceutical Company, Hangzhou, Zhejiang, P. R. China.
  • Zhu C; Huadong Global Development Center, Hangzhou ZhongMei HuaDong Pharmaceutical Company, Hangzhou, Zhejiang, P. R. China.
  • Yu B; Huadong Global Development Center, Hangzhou ZhongMei HuaDong Pharmaceutical Company, Hangzhou, Zhejiang, P. R. China.
  • Xu J; Huadong Global Development Center, Hangzhou ZhongMei HuaDong Pharmaceutical Company, Hangzhou, Zhejiang, P. R. China.
  • Song Y; Department of Respiratory Medicine, General Hospital of Eastern Theater Command, Nanjing, Jiangsu, P. R. China.
  • Wang K; Department of Respiratory and Critical Care Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.
Cancer Commun (Lond) ; 43(9): 1059-1063, 2023 09.
Article en En | MEDLINE | ID: mdl-37322852
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Cancer Commun (Lond) Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Cancer Commun (Lond) Año: 2023 Tipo del documento: Article